Dewhirst MW: Angiogenesis and blood flow. In: Teicher BA (ed) Drug Resistance in Oncology. New York, NY, Marcel Dekker 3–24, 1993 Google Scholar
Vaupel P: Oxygenation of solid tumors. In: Teicher BA (ed) Drug Resistance in Oncology. New York, NY, Marcel Dekker 53–85, 1993 Google Scholar
Sartorelli AC: Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res 48: 775, 1988 Google Scholar
Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449–6465, 1989 Google Scholar
Kennedy KA, Teicher BA, Rockwell SA, Sartorelli AC: The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol 29: 18, 1980 Google Scholar
Teicher BA, Lazo JS, Sartorelli AC: Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41: 73–81, 1981 Google Scholar
Jain RK: Determinants of tumor blood flow: a review. Cancer Res 48: 2641–2658, 1988 Google Scholar
Sevick EM, Jain RK: Geometric resistance to blood flow in solid tumors perfused_ex vivo:_ effects of tumor size and perfusion pressure. Cancer Res 49: 3513–3519, 1989 Google Scholar
Vaupel P, Frinak S, Bicher HI: Heterogeneous oxygen partial pressure and pH distribution C3H mouse mammary adenocarcinoma. Cancer Res 41: 2008–2013, 1981 Google Scholar
Vaupel P, Fortmeyer HP, Runkel S, Kallinowski F: Blood flow, oxygen consumption and tissue oxygenation of human breast cancer xenografts in nude rats. Cancer Res 47: 3496–3503, 1987 Google Scholar
Song CW, Lee I, Hasegawa T, Rhee JG, Levitt SH: Increase in pO2 and radiosensitivity of tumors by Fluosol-DA (20%) and carbogen. Cancer Res 47: 442–446, 1987 Google Scholar
Hasegawa T, Rhee JG, Levitt SH, Song CW: Increase in tumor pO2 by perfluorochemicals and carbogen. Int J Radiat Oncol Biol Phys 13: 569–574, 1987 Google Scholar
Gullino PM:In vivo utilization of oxygen and glucose by neoplastic tissue. Adv Exp Med Biol 75: 521–536, 1975 Google Scholar
Moulder JE, Rockwell S: Hypoxic fractions of solid tumors. Int J Radiat Oncol Biol Phys 10: 695–709, 1984 Google Scholar
Grau C, Overgaard J: Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 13: 301–309, 1988 Google Scholar
Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, Broder GJ: Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of therapy. Int J Radiat Oncol Biol Phys 14: 831–838, 1988 Google Scholar
Teicher BA, Holden SA, Rose CM: Effect of oxygen on the cytotoxicity and antitumor activity of etoposide. J Natl Cancer Inst 75: 1129–1133, 1985 Google Scholar
Teicher BA, Holden SA, Jacobs JL: Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res 47: 513–518, 1987 Google Scholar
Teicher BA, Crawford JM, Holden SA, Cathcart KNS: Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity. Cancer Res 47: 5036–5041, 1987 Google Scholar
Teicher BA, McIntosh-Lowe NL, Rose CM: Effect of various oxygenation conditions and Fluosol-DA on cancer chemotherapeutic agents. Biomat, Art Cells, Immobiol Biotech 16: 533–546, 1988 Google Scholar
Teicher BA, Waxman DJ, Holden SA, Wang Y, Clarke L, Alvarez Sotomayor E, Jones SM, Frei E: Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of_N,N′,N″_-triethylenethiophosphoramide. Cancer Res 49: 4996–5001, 1989 Google Scholar
Keyes SR, Rockwell S, Sartorelli AC: Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells_in vivo_ and_in vitro_. Cancer Res 45: 3642–3645, 1985 Google Scholar
Kallinowski F, Vaupel P: pH distributions in spontaneous and isotransplanted rat tumours. 58: 134–321, 1988
Herman TS, Teicher BA, Jochelson M, Clark J, Svensson G, Coleman CN: Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Int J Hyperthermia 4: 143–158, 1988 Google Scholar
Herman TS, Teicher BA, Collins LS: Effect of hypoxia and acidosis on the cytotoxicity of four platinum complexes at normal and hyperthermic temperatures. Cancer Res 48: 2342–2347, 1988 Google Scholar
Herman TS, Teicher BA, Holden SA, Collins LC: Interaction of hyperthermia and radiation: hypoxia and acidosis_in vitro_, tumor subpopulations_in vivo_. Cancer Res 49: 3338–3343, 1989 Google Scholar
Hahn GM, Shiu EC: Adaptation to low pH modifies thermal and thermochemical responses of mammalian cells. Int J Hyperthermia 2: 379–387, 1986 Google Scholar
Momparler RL:In vitro systems for evaluation of combination chemotherapy. Pharmacol Ther Part A Chemother Toxicol Metab Inhibitors 8: 21–35, 1980 Google Scholar
Born R, Hug O, Trott KR: The effect of prolonged hypoxia on growth and viability of Chinese hamster ovary cells. Int J Radiat Oncol Biol Phys 1: 687–697, 1976 Google Scholar
Siemann DW, Keng PC: Characterization of radiation resistant hypoxic cell subpopulations in KHT sarcomas (ii) Cell sorting. Br J Cancer 58: 296–300, 1988 Google Scholar
Barranco SC, Novak JK: Survival responses of dividing and nondividing mammalian cells after treatment with hydroxyurea, arabinosylcytosine, or Adriamycin. Cancer Res 34: 1616–1618, 1974 Google Scholar
Barranco SC, Novak JK, Humphrey RM: Response of mammalian cells following treatment with bleomycin and 1,3-bis(2-chloroethyl)-1-nitrosourea during plateau phase. Cancer Res 33: 691–694, 1973 Google Scholar
Bhuyan BK, Fraser TJ, Day KJ: Cell proliferation kinetics and drug sensitivity of exponential and stationary populations of cultured L1210 cells. Cancer Res 37: 1057–1063, 1977 Google Scholar
Twentyman PR: Comparative chemosensitivity of exponential versus plateau-phase cells in both_in vitro_ and_in vivo_ model systems. Cancer Treat Rep 60: 1719–1722, 1976 Google Scholar
Vaupel P: Hypoxia and neoplastic tissue. Microvasc Res 13: 399–408, 1977 Google Scholar
Teicher BA, Holden SA, Al-Achi A, Herman TS: Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations_in vivo_ in FSaIIC murine fibrosarcoma. Cancer Res 50: 3339–3344, 1990 Google Scholar
Powers WE, Tolmach LJ: A multicomponent x-ray survival curve for mouse lymphosarcoma cells irradiated_in vivo_. Nature (London) 197: 710–711, 1963 Google Scholar
Kallman RF: The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 105: 135–142, 1972 Google Scholar
Kallman RF, Rockwell S: In: Becker FF (ed) Cancer. New York, Plenum Press 225–279, 1977 Google Scholar
Rockwell S, Kallman RF: Cellular radiosensitivity and tumor radiation response in the EMT-6 tumor cell system. Radiat Res 53: 281–294, 1973 Google Scholar
Suit HD, Shalek RJ: Response of anoxic C3H mouse mammary carcinoma isotransplants (1–25 mm3) to × irradiation. J Natl Cancer Inst 31: 479–493, 1963 Google Scholar
Suit HD, Maeda M: Hyperbaric oxygen and radiobiology of the C3H mouse mammary carcinoma. J Natl Cancer Inst 39: 639–652, 1967 Google Scholar
Fowler JF, Morgan RL, Wood CAP: Pre-therapeutic experiments with the fast neutron beam from the medical research council cyclotron. Brit J Radiol 36: 77–80, 1963 Google Scholar
Suit HD, Suchato C: Hyperbaric oxygen and radiotherapy of a fibrosarcoma and of squamous-cell carcinoma of C3H mice. Radiology 89: 713–719, 1967 Google Scholar
Thomlinson RH, Craddock EA: The gross response of an experimental tumour to single doses of x-ray. Br J Cancer 21: 108–123, 1967 Google Scholar
Reinhold HS, De Bree C: Tumour cure rate and cell survival of a transplantable rat rhabdomyosarcoma following x-irradiation. Eur J Cancer 4: 367–374, 1968 Google Scholar
Barendsen GW, Broerse JJ: Experimental radiotherapy of a rat rhabdomyosarcoma with 15 MeV neutrons and 300 kV x-rays. I. Effects of single exposure. Eur J Cancer 5: 373–391, 1969 Google Scholar
Van Putten LM, Kallman RF: Oxygenation status of a transplantable tumor during fractionated radiation therapy. J Natl Cancer Inst 40: 441–451, 1968 Google Scholar
Van Putten LM: Tumor reoxygenation during fractionated radiotherapy: studies with a transplantable mouse osteosarcoma. Eur J Cancer 4: 173–182, 1968 Google Scholar
Thomlinson RH: In: Bond VP, Suit HD, Marcial V (eds) Conference on time and dose relationships in radiation biology as applied to radiotherapy. Springfield, Virginia, Brookhaven Natl Lab Rep 242–247, 1970 Google Scholar
Howes AE: An estimation of changes in the proportions and absolute numbers of hypoxic cells after irradiation of transplanted C3H mouse mammary tumours. Brit J Radiol 42: 441–447, 1969 Google Scholar
Moulder JE, Fischer JJ, Milardo R: Time-dose relationships for the cure of an experimental rat tumor with fractionated radiation. Int J Radiat Oncol Biol Phys 1: 431–438, 1976 Google Scholar
Teicher BA, Dupuis NP, Robinson MF, Kusumoto T, Liu M, Menon K: Reduced oxygenation in a rat mammary carcinoma post-radiation and reoxygenation with a perflubron emulsion/carbogen breathing. Int J Radiat Oncol Biol Phys: submitted, 1993
Okunieff P, Hoeckel M, Dunphy EP, Schlenger K, Knoop C, Vaupel P: Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys 26: 631–636, 1993 Google Scholar
Evans RG, Kimler BF, Morantz RA, Batnitzky S: Lack of complications in long-term survivors after treatment with fluosol® and oxygen as an adjuvant to radiation therapy for high-grade brain tumors. Int J Radiat Oncol Biol Phys 26: 649–652, 1993 Google Scholar
Martin L, Lartigau E, Weeger P, Lambin P, Le Ridant AM, Lusinchi A, Wibault P, Eschwege F, Luboinski B, Guichard M: Changes in the oxygenation of head and neck tumors during carbogen breathing. Radiat Therap Oncol 27: 123–130, 1993 Google Scholar
Teicher BA, Holden SA, Dupuis NP, Kusomoto T, Liu M, Liu F, Menon K: Oxygenation of the rat 9L gliosarcoma and the rat 13672 mammary carcinoma with various doses of a hemoglobin solution. Biomat Art Cells, Immobiol Biotech: in press, 1993
Teicher BA, Schwartz GN, Dupuis NP, Kusomoto T, Liu M, Liu F, Northey D: Oxygenation of human tumor xenografts in nude mice by a perfluorochemical emulsion and carbogen breathing. Biomat Art Cells, Immobiol Biotech: in press, 1993
Teicher BA, Herman TS, Frei III E: Perfluorochemical emulsions: Oxygen breathing in radiation sensitization and chemotherapy modulation. In: DeVita VTJ, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. Philadelphia, J.B. Lippincott Co 39–59, 1992 Google Scholar
Teicher BA, Herman TS: Use of fluosol-DA/oxygen breathing with radiation therapy and chemotherapy/radiation combinations. In: John MJ, Flam MS, Legha SS, Phillips TL (eds) Chemoradiation: an integrated approach to cancer treatment. Philadelphia, PA, Lea & Fibiger 140–158, 1993 Google Scholar
Teicher BA, Schwartz GN, Alvarez Sotomayor E, Robinson MF, Dupuis NP, Menon K: Oxygenation of tumors by a hemoglobin solution. J Cancer Res Clin Oncol: in press, 1993
Teicher BA, Holden SA, Menon K, Hopkins RE, Gawryl MS: Effect of a hemoglobin solution on the response of intracranial and subcutaneous 9L tumors to antitumor alkylating agents. Cancer Chemother Pharmacol: in press, 1993
Vitu-Loas L, Thomas C, Chavaudra N, Guichard M: Radiosensitivity, blood perfusion and tumour oxygenation after perflubron emulsion injection. Radiother Oncol 27: 149–155, 1993 Google Scholar
Suit HD, Sedlacek RS, Silver G, Dosoretz D: Pentobarbital anesthesia and the response of tumor and normal tissue in the C3Hf/sed mouse to radiation. Radiat Res 104: 47–65, 1985 Google Scholar
Henk JM, Kinkler PB, Smith CW: Radiotherapy and hyperbaric oxygen in head and neck cancer. Final report of first controlled clinical trial. Lancet 2: 101–103, 1977 Google Scholar
Bush RS, Jenkin RDT, Allt WEC, Beale FA, Bean H, Dembo AJ, Pringle JF: Definitive evidence for hypoxic cells influencing cure in chemotherapy. Br J Cancer 37 (Suppl III): 302–306, 1978 Google Scholar
Teicher BA, Rose CM: Perfluorochemical emulsion can increase tumor radiosensitivity. Science (Wash DC) 223: 934–936, 1984 Google Scholar
Teicher BA, Herman TS, Jones SM: Optimization of perfluorochemical levels with radiation therapy in mice. Cancer Res 49: 2693–2697, 1989 Google Scholar
Teicher BA, Rose CM: Oxygen-carrying perfluorochemical emulsion as an adjuvant to radiation therapy in mice. Cancer Res 44: 4285–4288, 1984 Google Scholar
Teicher BA, Rose CM: Effect of dose and scheduling on growth delay of the Lewis lung carcinoma produced by the perfluorochemical emulsion, Fluosol-DA. Int J Radiat Oncol Biol Phys 12: 1311–1313, 1986 Google Scholar
Teicher BA, Herman TS, Jones SM: Influence of scheduling, dose, and volume of administration of a perfluorochemical emulsion on tumor response to radiation therapy. Int J Radiat Oncol Biol Phys 19: 945–951, 1990 Google Scholar
Teicher BA, Herman TS, Rose CM: Effect of Fluosol-DA® on the response of intracranial 9L tumors to x-rays and BCNU. Int J Radiat Oncol Biol Phys 15: 1187–1192, 1988 Google Scholar
Lee I, Levitt SH, Song CW: Effects of Fluosol-DA 20% and carbogen on the radioresponse of SCK tumors and skin of A/J mice. Radiat Res 112: 173–182, 1987 Google Scholar
Lee I, Levitt SH, Song CW: Radiosensitization of murine tumors by Fluosol-DA 20%. Radiat Res 122: 275–279, 1990 Google Scholar
Martin DF, Porter EA, Fischer JJ, Rockwell S: Effect of a perfluorochemical emulsion on the radiation response of BA-1112 rhabdomyosarcomas. Radiat Res 112: 45–53, 1987 Google Scholar
Moulder JE, Dutreix J, Rockwell S, Siemann DW: Applicability of animal tumor data to cancer therapy in humans. Int J Radiat Oncol Biol Phys 14: 913–927, 1988 Google Scholar
Moulder JE, Fish BL: Tumor sensitization by the intermittent use of perfluorochemical emulsions and carbogen breathing in fractionated radiotherapy. In: Fielden EM, Fowler JF, Hendry JH, Scott D (eds) Proceedings of the 8th International Congress of Radiation Research. Taylor and Francis, Inc, London, 1987: 299 Google Scholar
Rockwell S, Mato TP, Irvin CG, Nierenburg M: Reactions of tumors and normal tissues in mice to irradiation in the presence and absence of a perfluorochemical emulsion. Int J Radiat Oncol Biol Phys 12: 1315–1318, 1986 Google Scholar
Song CW, Zhang WL, Pence DM, Lee I, Levitt SH: Increased radiosensitivity of tumors by perfluorochemicals and carbogen. Int J Radiat Oncol Biol Phys 11: 1833–1836, 1985 Google Scholar
Rose CM, Lustig R, McIntosh N, Teicher BA: A clinical trial of Fluosol-DA® 20% in advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 12: 1325–1327, 1986 Google Scholar
Lustig R, McIntosh-Lowe NL, Rose C, Haas J, Krasnow S, Spaulding M, Prosnitz L: Phase I/II study of Fluosol-DA and 100% oxygen breathing as an adjuvant to radiation in the treatment of advanced squamous cell tumors of the head and neck. Int J Radiat Oncol Biol Phys 16: 1587–1594, 1989 Google Scholar
Lustig R, Lowe N, Prosnitz L, Spaulding M, Cohen M, Stitt S, Brannon R: Fluosol and oxygen breathing as an adjuvant to radiation therapy in the treatment of locally advanced non-small cell carcinoma of the lung: results of a phase I/II study. Int J Radiat Oncol Biol Phys 19(1): 97–102, 1990 Google Scholar
Lee I, Kim JH, Levitt SH, Song CW: Increases in tumor response by pentoxifylline alone or in combination with nicotinamide. Int J Radiat Oncol Biol Phys 22: 425–429, 1992 Google Scholar
Teicher BA, Sotomayor EA, Robinson MF, Dupuis NP, Schwartz GN, Frei III E: Tumor oxygenation and radiosensitization by pentoxifylline and a perflubron emulsion/carbogen breathing. Int J Oncol 2: 13–21, 1993 Google Scholar
Duncan W: Exploitation of the oxygen enhancement ratio in clinical practice. Br Med Bull 29: 33, 1973 Google Scholar
Fowler JR, Thomlinson RH, Howes AE: Time-dose relationships in radiotherapy. Eur J Cancer 6: 207, 1970 Google Scholar
Hall EJ: Radiobiology for the Radiobiologist (Second ed). Philadelphia: Harper & Row, 1978: 235–243 Google Scholar
Carter SK, Crooke ST, Umezawa H: Bleomycin: current status and new developments. New York: Academic Press, 1978: Google Scholar
Twentyman PR: Bleomycin - mode of action with particular reference to the cell cycle. Pharm Ther 23: 417–441, 1984 Google Scholar
Ervin TJ, Weichselbaum R, Miller D, Meshad M, Posner M, Fabian R: Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM). Cancer Treat Rep 65: 787–791, 1981 Google Scholar
Shah PM, Shukla SN, Patel KM, Patel NL, Baboo HA, Patel DD: Effect of bleomycin-radiotherapy combination in management of head and neck squamous cell carcinoma. Cancer 48: 1106–1109, 1981 Google Scholar
Spaulding MB, Kahn A, Klotch D, Lorie Jr JM: Adjuvant chemotherapy in head and neck cancer. An update. Am J Surg 144: 432–436, 1982 Google Scholar
Hecht SM: The chemistry of activated bleomycin. Accounts Chem Res 144: 432–436, 1986 Google Scholar
Sausville EA, Peisach J, Horwitz SB: Effect of chelating agents and metal ions on the degradation of DNA by bleomycin. Biochemistry 17: 2740–2746, 1978 Google Scholar
Berry DE, Kilkuskie RE, Hecht SM: DNA damage induced by bleomycin in the presence of bibucaine is not predictive of cell growth inhibition. Biochemistry 24: 3214–3219, 1985 Google Scholar
Lown JW, Kil SK: The mechanism of the bleomycin-induced cleavage of DNA. Biochim Biophys Res Commun 77: 1150–1157, 1977 Google Scholar
Oberley LW, Buettner GR: The production of hydroxy radical by bleomycin and iron (II). FEBS Lett 97: 47–49, 1979 Google Scholar
Sugiura Y: Production of free radicals from phenol and tocopherol by bleomycin-iron (II). Biochim Biophys Res Commun 87: 649–653, 1979 Google Scholar
Caspary WJ, Niziak C, Lanzo DA, Friedman R, Bachur NR: Bleomycin A2: a ferrous oxide. Mol Pharmacol 16: 256–260, 1979 Google Scholar
D'Andrea AD, Haseltine WA: Sequence specific cleavage of DNA by the antitumor antibiotics neocarzinostatin and bleomycin. Proc Nat Acad Sci USA 75: 3608–3612, 1978 Google Scholar
Mirabelli CK, Ting A, Huang CH, Mong S, Crooke ST: Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res 42: 2779–2785, 1982 Google Scholar
Huang CH, Mirabelli CK, Jan Y, Crooke ST: Single-strand and double-strand deoxyribonucleic acid breaks produced by several bleomycin analogues. Biochemistry 20: 233–238, 1981 Google Scholar
Cunningham ML, Ringrose PS, Lokesh BR: Inhibition of the genotoxicity of bleomycin by superoxide dismutase. Mutation Research 135: 199–202, 1984 Google Scholar
Kross J, Henner WD, Haseltine WA, Rodrigueq L, Levin MD, Hecht SM: Structural basis for the deoxyribonucleic acid affinity of bleomycin. Biochemistry 21: 3711–3721, 1982 Google Scholar
Kross J, Henner WD, Hecht SM, Haseltine WA: Specificity of deoxyribonucleic acid cleavage by bleomycin, phleomycin, and tallysomycin. Biochemistry 21: 4310–4318, 1982 Google Scholar
Teicher BA, Lazo JS, Merrill WW, Filderman AE, Rose CM: Effect of Fluosol-DA/O2 on the antitumor activity and pulmonary toxicity of bleomycin. Cancer Chemother Pharmacol 18: 213–218, 1986 Google Scholar
Issell BF, Muggia FM, Carter SF: Etoposide (VP-16): current status and new developments. New York: Academic, 1984: Google Scholar
Long BH, Minocha A: Inhibition of topoisomerase II by VP-16-213 (etoposide), VM-26 (teniposide) and structured congeners as an explanation for_in vivo_ DNA breakage and cytotoxicity. Proc Amer Assoc Cancer Res 24: 1271, 1983 Google Scholar
Long BH, Musial ST, Brattain MG: Comparison of cytotoxicity and DNA breakage activity of congeners of epipodophyllotoxin including BP-16-213 and VM-26: a quantitative structure-activity relationship. Biochemistry 23: 1183–1188, 1984 Google Scholar
Pommier Y, Schwartz RE, Zwelling LA, Kerrigan D, Mattern MR, Charcosset JY, Jacquemin-Sablon A, Kohn KW: Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46: 611–616, 1986 Google Scholar
Ross WE: DNA topoisomerases as targets for cancer therapy. Biochem Pharmacol 34: 4191–4195, 1985 Google Scholar
Kalwinsky DK, Look AT, Ducore J, Fridland A: Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Res 43: 1592–1597, 1983 Google Scholar
Loike JD, Horwitz SB: Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry 15: 5443–5448, 1976 Google Scholar
Arnold AM, Whitehouse JM: Interaction of VP-16-213 on the intracellular degradation of DNA in HeLa cells. Cancer Chemother. Pharmacol 7: 123–126, 1982 Google Scholar
Van Maanen JMS, Holthuis JJ, Gobas F, de Vries J, W.J. vO, Emmelot P, Pinedo HM: Role of bioactivation in covalent binding of VP-16 to rat liver and HeLa cell microsomal proteins. Proc Amer Assoc Cancer Res 24: 319, 1983 Google Scholar
Wozniak AJ, Ross WE: DNA damage as a basis for 4′-dimethylepipodophyllotoxin-9-(4,6-_O_-ethylidene-β-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res 43: 120–124, 1983 Google Scholar
Wozniak AJ, Glisson BS, Hande KR, Ross WE: Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents. Cancer Res 44: 626–632, 1984 Google Scholar
Yalowich JC, Ross WE: Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells_in vitro_. Cancer Res 44: 3360–3365, 1984 Google Scholar
Teicher BA, Bernal SD, Holden SA, Cathcart KNS: Effect of Fluosol®-DA/carbogen on etoposide/alkylating agent antitumor activity. Cancer Chemother Pharmacol 21: 281–285, 1988 Google Scholar
Tanaka J, Teicher BA, Herman TS, Holden SA, Dezube B, Frei III E: Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity_in vivo_. Int J Cancer 48: 631–637, 1991 Google Scholar
Pfeffer MR, Teicher BA, Holden SA, Al-Achi A, Herman TS: The interaction of cisplatin plus etoposide with radiation ± hyperthermia. Int J Radiat Oncol Biol Phys 19: 1439–1447, 1991 Google Scholar
Myers CE: Anthracyclines. In: Chabner B (ed) Pharmacologic Principles of Cancer Treatment. Philadelphia, W.B. Saunders 416–434, 1982 Google Scholar
Kaye S, Merry S: Tumor cell resistance to anthracycline: A review. Cancer Chemother Rep 6: 91–106, 1985 Google Scholar
DiMarco A: Mode and mechanism of action. Cancer Chemother Rep 6: 91–106, 1975 Google Scholar
Donehower RC, Myers CE, Chabner BA: New developments on the mechanisms of action of antineoplastic drugs. Life Sci 25: 1–14, 1979 Google Scholar
Lown JW, Sim S-W, Majumdar KC, Chang R-Y: Strand scission of DNA by bound Adriamycin and daunorubicin in the presence of reducing agents. Biochim Biophys Res Commun 76: 705–710, 1977 Google Scholar
Bachur NR: Anthracycoine antibiotic pharmacology and metabolism. Cancer Treat Rep 63: 817–820, 1979 Google Scholar
Bachur NR, Gordon SL, Gee MV: Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol 13: 901–910, 1977 Google Scholar
Bachur NR, Gordon SL, Gee MV: A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 38: 1745–1750, 1978 Google Scholar
Handa K, Sato G: Generation of free radicals of quinone group-containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation. Jap J Cancer Res 66: 43–47, 1975 Google Scholar
Sato S, Iwaizumo M, Handa K, Tamura Y: Electron spin resonance study on the mode of generation of free radicals of daunomycin, Adriamycin and carbogquone in NAD(P) H-microsome system. Jap J Cancer Res 68: 603–608, 1968 Google Scholar
Moore HW: Bioactivation as a model for drug design bioreductive alkylation. Science 197: 527–532, 1977 Google Scholar
Smith E, Stratford IJ, Adams GE: The resistance of hypoxic mammalian cells to chemotherapeutic agents (Abstr). Br J Cancer 40: 316, 1979 Google Scholar
Harris JW, Shrieve DC: Effects of Adriamycin and x-rays on euoxic and hypoxic EMT6 cells_in vitro_. Int J Radiat Oncol Biol Phys 5: 1245–1248, 1979 Google Scholar
Tannock I: Response of aerobic and hypoxic cells in a solid tumor to Adriamycin and cyclophosphamide and interaction of the drugs with radiation. Cancer Res 42: 4921–4926, 1982 Google Scholar
Goodman J, Hochstein P: Generation of free radicals and lipid peroxidation by redox cycling of Adriamycin and daunomycin. Biochim Biophys Res Commun 77: 797, 1977 Google Scholar
Kalyanaraman B, Perez-Reyes E, Mason PR: Spintrapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. Biochim Biophys Acta 630: 119–130, 1980 Google Scholar
Fridovich I: The biology of oxygen radicals. Science 201: 875–880, 1978 Google Scholar
Teicher BA, Holden SA, Crawford JM: Effects of Fluosol®-DA and oxygen breathing on adriamycin antitumor activity and cardiac toxicity in mice. Cancer 61: 2196–2201, 1988 Google Scholar
Teicher BA, Holden SA: Survey of the effect of adding Fluosol-DA 20%/O2 to treatment with various chemotherapeutic agents. Cancer Treat Rep 71: 173–177, 1987 Google Scholar
Herman TS, Teicher BA, Varshney A, Khandekar V, Brann T: Effect of hypoxia and acidosis on the cytotoxicity of mitoxantrone, bisantrene and amsacrine and their platinum complexes at normal and hyperthermic temperatures. Anticancer Res 12: 827–836, 1992 Google Scholar
Bisset D, Kaye SB: Taxol and Taxotere: Current Status and Future Prospects. Eur J Cancer 29A(9): 1228–1231, 1993 Google Scholar
Heacock CS, Sutherland RS: Induction characteristics of oxygen-regulated proteins. Int J Radiat Oncol Biol Phys 12: 1287–1290, 1990 Google Scholar
Rice GC, Ling V, Schimke RT: Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (adriamycin resistance). Proc Nat Acad Sci USA 84: 9261–9264, 1987 Google Scholar
Schlappack OK, Zimmermann A, Hill RP: Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumour cells. Br J Cancer 64: 663–670, 1991 Google Scholar
Wilson RE, Keng PC, Sutherland RM: Drug resistance in Chinese hamster ovary cells during recovery from severe hypoxia. J Natl Cancer Inst 81: 1235–1240, 1989 Google Scholar
Wilson DA, Talley RD, Storch TG: Oxygen concentration regulates EGF-induced proliferation and EGF-receptor down regulation. Biochim Biophys Res Commun 153: 952–958, 1988 Google Scholar
Deguchi Y, Negoro S, Kishimoto S: c-fos expression in human skin fibroblasts by reperfusion after oxygen deficiency: a recovery change of human skin fibroblasts after oxygen deficiency stress. Biochim Biophys Res Commun 149: 1093–1098, 1987 Google Scholar
Rice GC, Hoy C, Schimke RT: Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Nat Acad Sci USA 83: 5978–5982, 1986 Google Scholar
Young SD, Hill RP: Effects of reoxygenation of cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. J Natl Cancer Inst 82: 371–380, 1990 Google Scholar
Sakata K, Tak Kwok T, Murphy BJ, Laderoute KR, Gordon GR, Sutherland RM: Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br J Cancer 64: 809–814, 1991 Google Scholar
Kalra R, Jones A-M, Kirk J, Adams GE, Stratford IJ: The effect of hypoxia on acquired drug resistance and response to epidermal growth factor in Chinese hamster lung fibroblasts and human breast-cancer cells_in vitro_. Int J Cancer 54: 650–655, 1993 Google Scholar
Osmak M, Perovic S: Multiple fractions of gamma rays induced resistance to cis-dichlorodiammineplatinum (II) and methotrexate in human HeLa cells. Int J Radiat Oncol Biol Phys 16: 1537–1541, 1989 Google Scholar
Hopwell LE, Moulder JE: Radiation induction of drug resistance in RIF-1 tumors and tumor cells. Radiat Res 120: 251–266, 1989 Google Scholar
Sharma RC, Schimke RT: Enhancement of the frequency of methotrexate resistance by γ-radiation in Chinese hamster ovary and mouse 3T3 cells. Cancer Res 49: 3861–3866, 1989 Google Scholar
Bedford P, Shellard SA, Walker MC, Whelan RDH, Masters JRW, Hill BT: Differential expression of collateral sensitivity or resistance to cisplatin in human bladder carcinoma cell lines pre-exposed_in vitro_ to either x-irradiation or cisplatin. Int J Cancer 40:681–686, 1987 Google Scholar
Kohn KW: Molecular mechanisms of cross-linking by alkylating agents and platinum complexes. In: Sartorelli AC, Lazo JS, Bertino JR (eds) Molecular actions and targets for cancer chemotherapeutic agents. New York, Academic Press, Inc 3–16, 1981 Google Scholar
Ross WE, Ewig RAG, Kohn K: Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links. Cancer Res 38: 1502–1506, 1978 Google Scholar
Zwelling LA, Michaels S, Schwartz H, Dobson PP, Kohn KW: DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to_cis_-diamminedichloroplatinum (II) and phenylalanine mustard. Cancer Res 41: 640–649, 1981 Google Scholar
Ahmed AR, Hombal SM: Cyclophosphamide (Cytoxan): a review on relevant pharmacology and clinical uses. J Am Acad Dermatol 11: 1115–1126, 1984 Google Scholar
Thomas ED: High dose therapy and bone marrow transplantation. Semin Oncol 12 [Suppl 6]: 15–20, 1985 Google Scholar
Borch RF, Millard JA: The mechanism of activation of 4-hydroperoxycyclophosphamide. J Med Chem 30: 427–431, 1987 Google Scholar
Kwon CH, Maddison K, Locastro L, Borch RF: Accelerated decomposition of 4-hydroperoxycyclophosphamide by human serum albumin. Cancer Res 47: 1505–1508, 1987 Google Scholar
Friedman OM, Myles A, Colvin OM: Cyclophosphamide and related phosphoramide mustards: current status and future prospects. In: Rosowsky A (ed) Advances in Cancer Chemotherapy. New York, Dekker 159–164, 1979 Google Scholar
Dewys WD: A dose-response study of resistance of leukemia L1210 to cyclophosphamide. J Natl Cancer Inst 50: 783–789, 1973 Google Scholar
Hilton J: Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and -resistant L1210 cells. Biochem Pharmacol 43: 1867–1872, 1984 Google Scholar
Sladek NE, Landkamer GJ: Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines. Cancer Res 45: 1549–1555, 1985 Google Scholar
Sladek NE, Low JE, Landkamer GJ: Collateral sensitivity to cross-linking agents exhibited by cultured L1210 cells resistant to oxazaphosphorines. Cancer Res 45: 625–629, 1985 Google Scholar
Boon MH, Parsons PG: Cyclophosphamide resistance developed in a human melanoma cell line. Cancer Treat Rep 68: 1239–1246, 1984 Google Scholar
D'Incalci M, Torti L, Damia G, Erba E, Morasca L, Garattini S: Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide. Cancer Res 43: 5674–5680, 1983 Google Scholar
Frondoza CG, Trivedi TP, Humphrey RL: Development of characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line. Cancer Treat Rep 66: 1535–1544, 1982 Google Scholar
McMillan TJ, Stephens TC, Steel GG: Development of drug resistance in a murine mammary tumor. Br J Cancer 52: 823–832, 1985 Google Scholar
Teicher BA, Herman TS, Holden SA, Cathcart KNS: The effect of Fluosol-DA and oxygenation status on the activity of cyclophosphamide_in vivo._ Cancer Chemother. Pharmacol 21: 286–291, 1988 Google Scholar
Teicher BA, Dupuis NP, Kusumoto T, Liu M, Liu F, Menon K, Schwartz GN, Frei III E: Decreased tumor oxygenation after cyclophosphamide reoxygenation and therapeutic enhancement with a perflubron emulsion/carbogen breathing. Int J Oncol in press, 1993
Nelson DF, Urtasun RC, Saunders WM, Gutin PH, Shelin GE: Recent and current investigations of radiation therapy of malignant gliomas. Semin Oncol 13: 46–55, 1986 Google Scholar
Shapiro WR: Therapy of adult malignant brain tumors: What have the clinical trials taught us? Semin Oncol 13: 38–45, 1986 Google Scholar
Wara WM: Radiation therapy for brain tumors. Cancer 55: 2291–2295, 1985 Google Scholar
Blasberg RG, Groothuis DR: Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Semin Oncol 13: 70–82, 1986 Google Scholar
Shapiro WR, Shapiro JR: Principles of brain tumor chemotherapy. Semin Oncol 13: 56–69, 1986 Google Scholar
Levin VA, Kabra P: Effectiveness of the nitrosourea as a function of lipid solubility for the chemotherapy of experimental rat brain tumors. Cancer Chemother Rep 58: 787–792, 1974 Google Scholar
Rosenblum ML, Wheeler KT, Wilson CB, Barker M, Kenebel KD:In vitro evaluation of_in vivo_ brain tumor chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 35: 1387–1391, 1975 Google Scholar
Tel E, Barker M, Levin VA, Wilson CB: Effect of combined surgery and BCNU (NSU 409962) on an animal brain tumor model. Cancer Chemother Rep 58: 627–631, 1974 Google Scholar
Teicher BA, Dupuis NP, Holden SA, Schwartz GN, Lester S, Frei III E: Definition and manipulation of tumor oxygenation. Cancer Res: submitted, 1993
Rockwell S: Use of perfluorochemical emulsion to improve oxygenation in a solid tumor. Int J Radiat Oncol Biol Phys 11: 97–103, 1985 Google Scholar
Moulder JE, Fish BL: Intermittent use of a perfluorochemical emulsion (Fluosol-DA 20%) and carbogen breathing with fractionated irradiation. Int J Radiat Oncol Biol Phys 15: 1193–1196, 1988 Google Scholar
Martin DF, Porter EA, Rockwell S, Fischer JJ: Enhancement of tumor radiation response by the combination of a perfluorochemical emulsion and hyperbaric oxygen. Int J Radiat Oncol Biol Phys 13: 747–751, 1987 Google Scholar
Sartorelli AC: The role of mitomycin antibiotics in the chemotherapy of solid tumors. Biochem Pharmacol 35: 67–69, 1986 Google Scholar
Kennedy KA, McGurl JD, Leonardis L, Alabaster O: pH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells. Cancer Res 45: 3541–3547, 1985 Google Scholar
Kennedy KA, Mimnaugh EG, Trush MA, Sinha BK: Effects of glutathione and ethylxanthate on mitomycin C activation by isolated rat hepatic or EMT6 mouse mammary tumor nuclei. Cancer Res 45: 4071–4076, 1985 Google Scholar
Keyes SR, Fracasso PM, Heimbrook DC, Rockwell S, Sligar SG, Sartorelli AC: Role of NADPH: cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C. Cancer Res 44: 5638–5643, 1984 Google Scholar
Keyes SR, Rockwell S, Sartorelli AC: Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicumarol_in vivo_ and_in vitro_. Cancer Res 45: 213–216, 1985 Google Scholar
Marshall RS, Rauth AM: Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant. Cancer Res 46: 2709–2713, 1986 Google Scholar
Rauth AM, Mohindra JK, Tannock IF: Activity of mitomycin C for aerobic and hypoxic cells_in vitro_ and_in vivo_. Cancer Res 43: 4154–4158, 1983 Google Scholar
Pritsos CA, Sartorelli AC: Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics. Cancer Res 46: 3528–3532, 1986 Google Scholar
Tomasz J, Jung M, Verdine G, Nakanishi K: Circular dichromism spectroscopy as a probe for the stereochemistry of aziridine cleavage reactions of mitomycin C. J Am Chem Soc 106: 7367–7370, 1984 Google Scholar
Tomasz M, Lipman R, Lee MS, Verdine GL, Nakanishi K: Reaction of acid-activated mitomycin C with calf thymus DNA and model guanines: elucidation of the base-catalyzed degradation of N7-alkylguanine nucleosides. Biochemistry 26: 2010–2027, 1987 Google Scholar
Papac RJ, Weissberg JB, Son YH, Sasaki C, Fischer DB, Lawrence R, Rockwell S, Sartorelli AC, Fischer JJ: Prospective randomized trial of radiation therapy (RT) ± mitomycin C (MC) in head and neck. Proceedings of the American Society of Clinical Oncologists Abstract 4921987
Fracasso PM, Sartorelli AC: Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells. Cancer Res 46: 3939–3944, 1986 Google Scholar
Kennedy KA, Rockwell S, Sartorelli AC: Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res 40: 2356–2360, 1980 Google Scholar
Rockwell S, Kennedy KA, Sartorelli AC: Mitomycin C a prototype bioreductive alkylating agent:in vitro studies of metabolism and cytotoxicity. Int J Radiat Oncol Biol Phys 8: 753–755, 1982 Google Scholar
Stratford IJ, Stephens MA: The differential hypoxic cytotoxicity of bioreductive agents determined_in vitro_ by the MTT assay. Int J Radiat Oncol Biol Phys 16: 973–976, 1989 Google Scholar
Holden SA, Herman TS, Teicher BA: Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA®/carbogen/radiation. Radiother Oncol 18: 59–70, 1990 Google Scholar
Herman TS, Teicher BA, Holden SA: Addition of mitomycin C to_cis_-diamminedichloroplatinum(II)/hyperthermia/radiation therapy in the FSaIIC fibrosarcoma. Int J Hyperthermia 7: 893–903, 1991 Google Scholar
Adams GE, Ahmen I, Sheldon PW_et al.: Radiation sensitization and chemopotentiation: RSU-1069, a compound more effective than misonidazole_in vitro and_in vivo_. Br J Cancer 49: 5571–5577, 1984 Google Scholar
Chaplin DJ, Durand RE, Stratford IJ, Jenkins TC: The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor. Int J Radiat Oncol Biol Phys 12: 1091–1095, 1986 Google Scholar
Franko AJ: Misonidazole and other hypoxia markers. Metabolism and applications. Int J Radiat Oncol Biol Phys 12: 1195–1202, 1986 Google Scholar
Hill RP: Sensitizers and radiation dose fractionation: results and interpretations. Int J Radiat Oncol Biol Phys 12: 1049–1054, 1986 Google Scholar
Laderoute KR, Eryavec E, McClelland RA, Rauth AM: The production of strand breaks in DNA in the presence of the hydroxylamine of SR-2058 (1-[_N_-(2-hydroxyethyl)acetamido]-2-nitroimidazole). Int J Radiat Oncol Biol Phys 12: 1215–1218, 1986 Google Scholar
McNally NJ: Enhancement of chemotherapy agents. Int J Radiat Oncol Biol Phys 8: 593–598, 1982 Google Scholar
Roizen-Towle L, Hall EJ, Piro JP: Oxygen dependence for chemosensitization by misonidazole. Br J Cancer 54: 919–924, 1986 Google Scholar
Siemann DW: Modification of chemotherapy by nitroimidazoles. Int J Radiat Oncol Biol Phys 10: 1585–1594, 1984 Google Scholar
Teicher BA, Pfeffer MR, Alvarez Sotomayor E, Herman TS: DNA cross-linking and pharmacokinetic parameters in target tissues with cis-diamminedichloroplatinum (II) and etanidazole with or without hyperthermia. Int J Hyperthermia 7: 773–784, 1991 Google Scholar
Steel GG, Peckman MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Oncol Biol Phys 15: 85–91, 1979 Google Scholar
Teicher BA, Holden SA, Jones SM, Eder JP, Herman TS: Influence of scheduling on two-drug combinations of alkylating agents_in vivo_. Cancer Chemother Pharmacol 25: 161–166, 1989 Google Scholar
Teicher BA, Herman TS, Shulman L, Bubley G, Coleman CN, Frei III E: Combination of etanidazole with cyclophosphamide and platinum complexes. Cancer Chemother Pharmacol 28: 153–158, 1991 Google Scholar
Teicher BA, Holden SA, Ara G, Sotomayor EA, Menon K, Tarbell NJ and Sallan SE: Etanidazole as a modulator of combined modality therapy in the rat 9L gliosarcoma. Int J Oncol 1: 625–630, 1992 Google Scholar
Teicher BA, Herman TS, Tanaka J, Eder JP, Holden SA, Bubley G, Coleman CN, Frei E: Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. Cancer Res 51: 1086–1091, 1991 Google Scholar
Zeman EM, Hirst VK, Lemmon MJ, Brown JM: Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol 12: 209–218, 1988 Google Scholar
Zeman EM, Brown JM: Pre- and post-irradiation radiosensitization by SR 4233. Int J Radiat Oncol Biol Phys 16: 967–971, 1989 Google Scholar
Zeman EM, Baker MA, Lemmon MJ, Pearson CI, Adams JA, Brown JM, Lee WW, Tracy M: Structure-activity relationships for benzotriazine di-_N_-oxides. Int J Radiat Oncol Biol Phys 16: 977–981, 1989 Google Scholar
Sun JR, Brown JM: Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. Cancer Res 49: 5664–5670, 1989 Google Scholar
Laderoute K, Wardman P, Rauth AM: Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233). Biochem Pharmacol 37: 1487–1495, 1988 Google Scholar
Baker MA, Zeman EM, Hirst VK, Brown JM: Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res 48: 5947–5952, 1988 Google Scholar
Costa AK, Baker MA, Brown JM, Trudell JR:In vitro hepatotoxicity of SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide), a hypoxic cytotoxin and potential antitumor agent. Cancer Res 49: 925–929, 1989 Google Scholar
Herman TS, Teicher BA, Coleman CN: The interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system_in vitro_ and_in vivo_. Cancer Res 50: 5055–5059, 1990 Google Scholar
Brown JM, Lemmon MJ: Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50(24): 7745–7749, 1990 Google Scholar
Walton MI, Workman P: Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-_N_-oxide hypoxic cell cytotoxin. Biochem Pharmacol 39: 1735–1742, 1990 Google Scholar
Biedermann KA, Brown JM: Comparison between x-rays and SR 4233 for cytotoxicity and repair of potentially lethal damage in human cells. Int J Radiat Biol 56: 813–816, 1989 Google Scholar
Zeman EM, Lemmon MJ, Brown JM: Aerobic radiosensitization by SR 4233_in vitro_ and_in vivo_. Int J Radiat Oncol Biol Phys 18: 125–132, 1990 Google Scholar
Brown JM: SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67(6): 1163–1170, 1993 Google Scholar
Holden SA, Teicher BA, Ara G, Herman TS, Coleman CN: Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. J Natl Cancer Inst 84: 187–193, 1992 Google Scholar
Adams GE, Ahmed I, Sheldon PW, Stratford IJ: RSU-1069 a 2-nitroimidazole containing an alkylating group: high efficacy as a radio- and chemosensitiser_in vitro_ and_in vivo_. Int J Radiat Oncol Biol Phys 10: 1653–1656, 1984 Google Scholar
Workman P, Stratford IJ: The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Met Rev 12: 73–82, 1993 Google Scholar
Siemann DW, Alliet K, Maddison K, Wolf K: Enhancement of the antitumor efficacy of lomustine by the radiosensitizer RSU-10690. Cancer Treat Rep 69: 1409–1414, 1985 Google Scholar
Siemann DW, Maddison K, Wolf K: Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU-1069. Int J Radiat Oncol Biol Phys 10: 1657–1660, 1984 Google Scholar
Walton MI, Workman P: Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU-1069 in mice. Cancer Chemother Pharmacol 22: 275–281, 1988 Google Scholar
Walling JM, Deacon J, Holliday S, Stratford IJ: High uptake of RSU-1069 and it analogues into melanotic melanomas. Cancer Chemother Pharmacol 24: 28–32, 1989 Google Scholar
Teicher BA, Herman TS, Holden SA, Rudolph MB: Effect of oxygenation, pH and hyperthermia on RSU-1069_in vitro_ and_in vivo_ with radiation in the FSaIIC murine fibrosarcoma. Cancer Letters 59: 109–117, 1991 Google Scholar
Teicher BA, Holden SA, Ara G, Ha CS, Herman TS, Northey D: A new concentrated perfluorochemical emulsion and carbogen breathing as a adjuvant to treatment with antitumor alkylating agents. J Cancer Res Clin Oncol 118: 509–514, 1992 Google Scholar
Teicher BA, Herman TS, Hopkins RE, Menon K: Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents. J Cancer Res Clin Oncol 118: 123–128, 1992 Google Scholar